| Year |
Citation |
Score |
| 2016 |
Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, et al. A First-in-Human Phase I Study of the ATP-Competitive Akt Inhibitor Ipatasertib (GDC-0068) Demonstrates Robust and Safe Targeting of Akt in Patients with Solid Tumors. Cancer Discovery. PMID 27872130 DOI: 10.1158/2159-8290.Cd-16-0512 |
0.309 |
|
| 2016 |
Budha NR, Ji T, Musib L, Eppler S, Dresser M, Chen Y, Jin JY. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Clinical Pharmacokinetics. PMID 27225997 DOI: 10.1007/S40262-016-0412-5 |
0.366 |
|
| 2016 |
Tolcher A, Bendell JC, Papadopoulos KP, Burris HA, Patnaik A, Fairbrother WJ, Wong H, Budha N, Darbonne WC, Peale F, Mamounas M, Royer-Joo S, Yu R, Portera CC, Infante JR. A PHASE I DOSE ESCALATION STUDY EVALUATING THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF CUDC-427, A POTENT, ORAL, MONOVALENT IAP ANTAGONIST, IN PATIENTS WITH REFRACTORY SOLID TUMORS. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27076626 DOI: 10.1158/1078-0432.Ccr-16-0308 |
0.358 |
|
| 2016 |
Bonate PL, Ahamadi M, Budha N, de la Peña A, Earp JC, Hong Y, Karlsson MO, Ravva P, Ruiz-Garcia A, Struemper H, Wade JR. Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group. Journal of Pharmacokinetics and Pharmacodynamics. PMID 26837775 DOI: 10.1007/S10928-016-9464-2 |
0.353 |
|
| 2015 |
Chen Y, Ma F, Lu T, Budha N, Jin JY, Kenny JR, Wong H, Hop CE, Mao J. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction. Clinical Pharmacokinetics. PMID 26692192 DOI: 10.1007/S40262-015-0352-5 |
0.387 |
|
| 2015 |
Han K, Jin JY, Marchand M, Eppler S, Choong N, Hack SP, Tikoo N, Bruno R, Dresser M, Musib L, Budha NR. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology. PMID 26365290 DOI: 10.1200/Jco.2015.33.15_Suppl.2573 |
0.327 |
|
| 2015 |
Budha NR, Leabman M, Jin JY, Wada DR, Baruch A, Peng K, Tingley WG, Davis JD. Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9. The Aaps Journal. 17: 881-90. PMID 25823668 DOI: 10.1208/S12248-015-9750-8 |
0.369 |
|
| 2014 |
Peng K, Xu K, Liu L, Hendricks R, Delarosa R, Erickson R, Budha N, Leabman M, Song A, Kaur S, Fischer SK. Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study. Mabs. 6: 1500-8. PMID 25484037 DOI: 10.4161/Mabs.36208 |
0.332 |
|
| 2014 |
Yago MR, Frymoyer A, Benet LZ, Smelick GS, Frassetto LA, Ding X, Dean B, Salphati L, Budha N, Jin JY, Dresser MJ, Ware JA. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. The Aaps Journal. 16: 1358-65. PMID 25274610 DOI: 10.1208/S12248-014-9673-9 |
0.381 |
|
| 2013 |
Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, Lum BL, Budha N, Holden SN, Benet LZ, Frymoyer A, Dresser MJ, Ware JA. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Molecular Pharmaceutics. 10: 4055-62. PMID 24044612 DOI: 10.1021/Mp400403S |
0.345 |
|
| 2013 |
Wong H, Gould SE, Budha N, Darbonne WC, Kadel EE, La H, Alicke B, Halladay JS, Erickson R, Portera C, Tolcher AW, Infante JR, Mamounas M, Flygare JA, Hop CE, et al. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 2104-13. PMID 24041744 DOI: 10.1124/Dmd.113.053926 |
0.397 |
|
| 2013 |
Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY. A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharmaceutics & Drug Disposition. 34: 141-54. PMID 23225350 DOI: 10.1002/Bdd.1830 |
0.306 |
|
| 2013 |
Tingley W, Luca D, Leabman M, Budha N, Kahn R, Baruch A, Cowan K, Davis JC. GW24-e2907 Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study Heart. 99: A153.2-A153. DOI: 10.1136/Heartjnl-2013-304613.423 |
0.352 |
|
| 2013 |
Tingley W, Luca D, Leabman M, Budha N, Kahn R, Baruch A, Cowan K, Davis JC. Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study European Heart Journal. 34: P4183-P4183. DOI: 10.1093/Eurheartj/Eht309.P4183 |
0.353 |
|
| 2012 |
Wong H, Budha NR, West K, Blackwood E, Ware JA, Yu R, Darbonne WC, Gould SE, Steigerwalt R, Erickson R, Hop CE, LoRusso P, Eckhardt SG, Wagner A, Chan IT, et al. Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis. Toxicological Sciences : An Official Journal of the Society of Toxicology. 130: 205-13. PMID 22843607 DOI: 10.1093/Toxsci/Kfs235 |
0.333 |
|
| 2012 |
Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, Holden SN, Benet LZ, Ware JA. Drug absorption interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the achilles heel of targeted therapy Clinical Pharmacology and Therapeutics. 92: 203-213. PMID 22739140 DOI: 10.1038/Clpt.2012.73 |
0.329 |
|
| 2012 |
Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, Cohen F, Deshayes K, Doerner K, Eckhardt SG, Elliott LO, Feng B, Franklin MC, Reisner SF, Gazzard L, et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). Journal of Medicinal Chemistry. 55: 4101-13. PMID 22413863 DOI: 10.1021/Jm300060K |
0.351 |
|
| 2011 |
Budha NR, Kovar A, Meibohm B. Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects. The Aaps Journal. 13: 650-61. PMID 22005901 DOI: 10.1208/S12248-011-9302-9 |
0.525 |
|
| 2011 |
Yan Y, Wagle M, Punnoose E, Musib L, Budha N, Nannini M, Lin K, Liederer BM, Murli S, Ramakrishnan V, Patel P, Cervantes A, Tabernero J. Abstract B154: A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B154 |
0.353 |
|
| 2009 |
Budha NR, Lee RB, Hurdle JG, Lee RE, Meibohm B. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis (Edinburgh, Scotland). 89: 378-85. PMID 19748318 DOI: 10.1016/J.Tube.2009.08.002 |
0.573 |
|
| 2008 |
Zhang Y, Mehrotra N, Budha NR, Christensen ML, Meibohm B. A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens. Clinica Chimica Acta; International Journal of Clinical Chemistry. 398: 105-12. PMID 18796299 DOI: 10.1016/J.Cca.2008.08.023 |
0.501 |
|
| 2008 |
Hurdle JG, Lee RB, Budha NR, Carson EI, Qi J, Scherman MS, Cho SH, McNeil MR, Lenaerts AJ, Franzblau SG, Meibohm B, Lee RE. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. The Journal of Antimicrobial Chemotherapy. 62: 1037-45. PMID 18693235 DOI: 10.1093/Jac/Dkn307 |
0.55 |
|
| 2008 |
Budha NR, Mehrotra N, Tangallapally R, Rakesh, Qi J, Daniels AJ, Lee RE, Meibohm B. Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents. The Aaps Journal. 10: 157-65. PMID 18446516 DOI: 10.1208/S12248-008-9017-8 |
0.556 |
|
| 2008 |
Budha NR, Lee RE, Meibohm B. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs. Current Medicinal Chemistry. 15: 809-25. PMID 18393850 DOI: 10.2174/092986708783955509 |
0.573 |
|
| 2007 |
Tangallapally RP, Sun D, Rakesh, Budha N, Lee RE, Lenaerts AJ, Meibohm B, Lee RE. Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorganic & Medicinal Chemistry Letters. 17: 6638-42. PMID 17937983 DOI: 10.1016/J.Bmcl.2007.09.048 |
0.561 |
|
| Show low-probability matches. |